nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluocinonide—SERPINA6—oviduct—ovarian cancer	0.0823	0.155	CbGeAlD
Fluocinonide—SMO—myometrium—ovarian cancer	0.0478	0.0899	CbGeAlD
Fluocinonide—SMO—embryo—ovarian cancer	0.046	0.0864	CbGeAlD
Fluocinonide—SMO—uterine cervix—ovarian cancer	0.0372	0.0699	CbGeAlD
Fluocinonide—SMO—endometrium—ovarian cancer	0.0336	0.0633	CbGeAlD
Fluocinonide—SMO—uterus—ovarian cancer	0.031	0.0583	CbGeAlD
Fluocinonide—SMO—female reproductive system—ovarian cancer	0.0279	0.0524	CbGeAlD
Fluocinonide—SMO—female gonad—ovarian cancer	0.0254	0.0477	CbGeAlD
Fluocinonide—SMO—vagina—ovarian cancer	0.0252	0.0474	CbGeAlD
Fluocinonide—SMO—testis—ovarian cancer	0.0225	0.0423	CbGeAlD
Fluocinonide—SMO—Hair Follicle Development: Induction (Part 1 of 3)—TP63—ovarian cancer	0.0166	0.0862	CbGpPWpGaD
Fluocinonide—SMO—lymph node—ovarian cancer	0.0163	0.0307	CbGeAlD
Fluocinonide—SERPINA6—female reproductive system—ovarian cancer	0.0153	0.0289	CbGeAlD
Fluocinonide—SERPINA6—bone marrow—ovarian cancer	0.0145	0.0272	CbGeAlD
Fluocinonide—NR3C1—myometrium—ovarian cancer	0.0115	0.0217	CbGeAlD
Fluocinonide—NR3C1—embryo—ovarian cancer	0.0111	0.0208	CbGeAlD
Fluocinonide—NR3C1—Regulation of Androgen receptor activity—SPDEF—ovarian cancer	0.0109	0.0568	CbGpPWpGaD
Fluocinonide—NR3C1—epithelium—ovarian cancer	0.00905	0.017	CbGeAlD
Fluocinonide—NR3C1—uterine cervix—ovarian cancer	0.00897	0.0169	CbGeAlD
Fluocinonide—NR3C1—decidua—ovarian cancer	0.00855	0.0161	CbGeAlD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—CD82—ovarian cancer	0.00848	0.0442	CbGpPWpGaD
Fluocinonide—NR3C1—endometrium—ovarian cancer	0.00811	0.0153	CbGeAlD
Fluocinonide—Secondary infection—Epirubicin—ovarian cancer	0.00797	0.0306	CcSEcCtD
Fluocinonide—NR3C1—gonad—ovarian cancer	0.00753	0.0142	CbGeAlD
Fluocinonide—NR3C1—uterus—ovarian cancer	0.00748	0.0141	CbGeAlD
Fluocinonide—Secondary infection—Doxorubicin—ovarian cancer	0.00737	0.0283	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—TOP1—ovarian cancer	0.00692	0.036	CbGpPWpGaD
Fluocinonide—NR3C1—female reproductive system—ovarian cancer	0.00672	0.0126	CbGeAlD
Fluocinonide—Skin exfoliation—Melphalan—ovarian cancer	0.00665	0.0256	CcSEcCtD
Fluocinonide—NR3C1—Nuclear Receptors—NR5A1—ovarian cancer	0.00654	0.034	CbGpPWpGaD
Fluocinonide—Folliculitis—Paclitaxel—ovarian cancer	0.00651	0.025	CcSEcCtD
Fluocinonide—NR3C1—bone marrow—ovarian cancer	0.00635	0.0119	CbGeAlD
Fluocinonide—NR3C1—female gonad—ovarian cancer	0.00612	0.0115	CbGeAlD
Fluocinonide—NR3C1—vagina—ovarian cancer	0.00608	0.0114	CbGeAlD
Fluocinonide—Skin exfoliation—Vinorelbine—ovarian cancer	0.00581	0.0223	CcSEcCtD
Fluocinonide—Eruption—Docetaxel—ovarian cancer	0.00564	0.0217	CcSEcCtD
Fluocinonide—Infection—Carboplatin—ovarian cancer	0.00551	0.0212	CcSEcCtD
Fluocinonide—Leukoderma—Epirubicin—ovarian cancer	0.00551	0.0212	CcSEcCtD
Fluocinonide—NR3C1—testis—ovarian cancer	0.00542	0.0102	CbGeAlD
Fluocinonide—Dizziness—Altretamine—ovarian cancer	0.00531	0.0204	CcSEcCtD
Fluocinonide—NR3C1—Nuclear Receptor transcription pathway—NR5A1—ovarian cancer	0.00517	0.0269	CbGpPWpGaD
Fluocinonide—Leukoderma—Doxorubicin—ovarian cancer	0.0051	0.0196	CcSEcCtD
Fluocinonide—Pain—Carboplatin—ovarian cancer	0.00474	0.0182	CcSEcCtD
Fluocinonide—SMO—Signaling events mediated by the Hedgehog family—PIK3CA—ovarian cancer	0.00454	0.0236	CbGpPWpGaD
Fluocinonide—NR3C1—Signaling events mediated by HDAC Class II—HDAC6—ovarian cancer	0.00421	0.0219	CbGpPWpGaD
Fluocinonide—SMO—Hair Follicle Development: Induction (Part 1 of 3)—CTNNB1—ovarian cancer	0.00408	0.0212	CbGpPWpGaD
Fluocinonide—NR3C1—lymph node—ovarian cancer	0.00393	0.00739	CbGeAlD
Fluocinonide—Skin exfoliation—Paclitaxel—ovarian cancer	0.00391	0.015	CcSEcCtD
Fluocinonide—Fluticasone Propionate—PGR—ovarian cancer	0.00382	0.242	CrCbGaD
Fluocinonide—Eruption—Epirubicin—ovarian cancer	0.00381	0.0146	CcSEcCtD
Fluocinonide—Folliculitis—Epirubicin—ovarian cancer	0.00372	0.0143	CcSEcCtD
Fluocinonide—SMO—Signaling events mediated by the Hedgehog family—AKT1—ovarian cancer	0.00371	0.0193	CbGpPWpGaD
Fluocinonide—Eruption—Doxorubicin—ovarian cancer	0.00352	0.0135	CcSEcCtD
Fluocinonide—Betamethasone—PGR—ovarian cancer	0.0035	0.221	CrCbGaD
Fluocinonide—Folliculitis—Doxorubicin—ovarian cancer	0.00345	0.0132	CcSEcCtD
Fluocinonide—Swelling—Paclitaxel—ovarian cancer	0.00337	0.0129	CcSEcCtD
Fluocinonide—Skin exfoliation—Docetaxel—ovarian cancer	0.00331	0.0127	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—GADD45A—ovarian cancer	0.00331	0.0172	CbGpPWpGaD
Fluocinonide—SMO—Hair Follicle Development: Induction (Part 1 of 3)—MYC—ovarian cancer	0.0033	0.0172	CbGpPWpGaD
Fluocinonide—Nasal congestion—Paclitaxel—ovarian cancer	0.00326	0.0125	CcSEcCtD
Fluocinonide—NR3C1—Nuclear Receptors—PGR—ovarian cancer	0.00326	0.017	CbGpPWpGaD
Fluocinonide—SMO—Hair Follicle Development: Induction (Part 1 of 3)—EGFR—ovarian cancer	0.00323	0.0168	CbGpPWpGaD
Fluocinonide—Immune system disorder—Topotecan—ovarian cancer	0.00323	0.0124	CcSEcCtD
Fluocinonide—Immune system disorder—Melphalan—ovarian cancer	0.00316	0.0121	CcSEcCtD
Fluocinonide—NR3C1—Endoderm Differentiation—HNF1B—ovarian cancer	0.00303	0.0158	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—CHEK2—ovarian cancer	0.00302	0.0157	CbGpPWpGaD
Fluocinonide—Glycosuria—Epirubicin—ovarian cancer	0.00289	0.0111	CcSEcCtD
Fluocinonide—Swelling—Docetaxel—ovarian cancer	0.00286	0.011	CcSEcCtD
Fluocinonide—Infection—Chlorambucil—ovarian cancer	0.00283	0.0109	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—BRCA1—ovarian cancer	0.00283	0.0147	CbGpPWpGaD
Fluocinonide—Immune system disorder—Vinorelbine—ovarian cancer	0.00276	0.0106	CcSEcCtD
Fluocinonide—Dry skin—Paclitaxel—ovarian cancer	0.00272	0.0105	CcSEcCtD
Fluocinonide—Glycosuria—Doxorubicin—ovarian cancer	0.00267	0.0103	CcSEcCtD
Fluocinonide—Erythema—Vinorelbine—ovarian cancer	0.00266	0.0102	CcSEcCtD
Fluocinonide—Nasopharyngitis—Paclitaxel—ovarian cancer	0.00266	0.0102	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Topotecan—ovarian cancer	0.00263	0.0101	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Melphalan—ovarian cancer	0.00258	0.00989	CcSEcCtD
Fluocinonide—NR3C1—Nuclear Receptor transcription pathway—PGR—ovarian cancer	0.00257	0.0134	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—BRCA2—ovarian cancer	0.00256	0.0133	CbGpPWpGaD
Fluocinonide—Infection—Topotecan—ovarian cancer	0.00252	0.00969	CcSEcCtD
Fluocinonide—Nervous system disorder—Topotecan—ovarian cancer	0.00249	0.00957	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—CCNE1—ovarian cancer	0.00248	0.0129	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—ABCB1—ovarian cancer	0.00248	0.0129	CbGpPWpGaD
Fluocinonide—Infection—Melphalan—ovarian cancer	0.00247	0.00949	CcSEcCtD
Fluocinonide—Skin disorder—Topotecan—ovarian cancer	0.00247	0.00947	CcSEcCtD
Fluocinonide—Pain—Chlorambucil—ovarian cancer	0.00244	0.00937	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—TYMS—ovarian cancer	0.00243	0.0127	CbGpPWpGaD
Fluocinonide—Skin disorder—Melphalan—ovarian cancer	0.00241	0.00928	CcSEcCtD
Fluocinonide—NR3C1—AP-1 transcription factor network—ATF3—ovarian cancer	0.00232	0.0121	CbGpPWpGaD
Fluocinonide—Hyperglycaemia—Paclitaxel—ovarian cancer	0.00232	0.0089	CcSEcCtD
Fluocinonide—Dermatitis contact—Epirubicin—ovarian cancer	0.00231	0.00889	CcSEcCtD
Fluocinonide—Dry skin—Docetaxel—ovarian cancer	0.00231	0.00887	CcSEcCtD
Fluocinonide—Nasopharyngitis—Docetaxel—ovarian cancer	0.00225	0.00866	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—ovarian cancer	0.00225	0.00864	CcSEcCtD
Fluocinonide—Skin exfoliation—Epirubicin—ovarian cancer	0.00224	0.00859	CcSEcCtD
Fluocinonide—Pain—Topotecan—ovarian cancer	0.00217	0.00834	CcSEcCtD
Fluocinonide—Infection—Vinorelbine—ovarian cancer	0.00216	0.00829	CcSEcCtD
Fluocinonide—Dermatitis contact—Doxorubicin—ovarian cancer	0.00214	0.00822	CcSEcCtD
Fluocinonide—Nervous system disorder—Vinorelbine—ovarian cancer	0.00213	0.00818	CcSEcCtD
Fluocinonide—Pain—Melphalan—ovarian cancer	0.00213	0.00817	CcSEcCtD
Fluocinonide—Skin disorder—Vinorelbine—ovarian cancer	0.00211	0.00811	CcSEcCtD
Fluocinonide—Hypersensitivity—Chlorambucil—ovarian cancer	0.0021	0.00807	CcSEcCtD
Fluocinonide—Skin exfoliation—Doxorubicin—ovarian cancer	0.00207	0.00794	CcSEcCtD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—ATF3—ovarian cancer	0.00206	0.0107	CbGpPWpGaD
Fluocinonide—SMO—Hedgehog signaling events mediated by Gli proteins—AKT1—ovarian cancer	0.00206	0.0107	CbGpPWpGaD
Fluocinonide—Dexamethasone—PGR—ovarian cancer	0.00203	0.129	CrCbGaD
Fluocinonide—Pruritus—Chlorambucil—ovarian cancer	0.00202	0.00775	CcSEcCtD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—SMARCA4—ovarian cancer	0.00192	0.01	CbGpPWpGaD
Fluocinonide—NR3C1—Adipogenesis—RBL2—ovarian cancer	0.00191	0.00993	CbGpPWpGaD
Fluocinonide—Dexamethasone—CYP1B1—ovarian cancer	0.0019	0.12	CrCbGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—ESR1—ovarian cancer	0.00189	0.00984	CbGpPWpGaD
Fluocinonide—Hypersensitivity—Topotecan—ovarian cancer	0.00187	0.00719	CcSEcCtD
Fluocinonide—Pain—Vinorelbine—ovarian cancer	0.00186	0.00714	CcSEcCtD
Fluocinonide—Immune system disorder—Paclitaxel—ovarian cancer	0.00186	0.00714	CcSEcCtD
Fluocinonide—Hypersensitivity—Melphalan—ovarian cancer	0.00183	0.00704	CcSEcCtD
Fluocinonide—SMO—Signaling Pathways—HSD17B6—ovarian cancer	0.00182	0.0095	CbGpPWpGaD
Fluocinonide—Pruritus—Topotecan—ovarian cancer	0.0018	0.0069	CcSEcCtD
Fluocinonide—Erythema—Paclitaxel—ovarian cancer	0.00179	0.00688	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—APC—ovarian cancer	0.00179	0.00931	CbGpPWpGaD
Fluocinonide—Pruritus—Melphalan—ovarian cancer	0.00176	0.00676	CcSEcCtD
Fluocinonide—NR3C1—Signaling events mediated by HDAC Class II—ESR1—ovarian cancer	0.00174	0.00905	CbGpPWpGaD
Fluocinonide—NR3C1—Nuclear Receptors—ESR1—ovarian cancer	0.00174	0.00905	CbGpPWpGaD
Fluocinonide—Fluticasone furoate—ABCB1—ovarian cancer	0.0017	0.108	CrCbGaD
Fluocinonide—Dizziness—Topotecan—ovarian cancer	0.00168	0.00645	CcSEcCtD
Fluocinonide—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—MAPK3—ovarian cancer	0.00162	0.00843	CbGpPWpGaD
Fluocinonide—Rash—Topotecan—ovarian cancer	0.0016	0.00615	CcSEcCtD
Fluocinonide—Hypersensitivity—Vinorelbine—ovarian cancer	0.0016	0.00615	CcSEcCtD
Fluocinonide—Dermatitis—Topotecan—ovarian cancer	0.0016	0.00614	CcSEcCtD
Fluocinonide—Headache—Topotecan—ovarian cancer	0.00159	0.00611	CcSEcCtD
Fluocinonide—Immune system disorder—Docetaxel—ovarian cancer	0.00157	0.00605	CcSEcCtD
Fluocinonide—Rash—Melphalan—ovarian cancer	0.00157	0.00602	CcSEcCtD
Fluocinonide—Dermatitis—Melphalan—ovarian cancer	0.00157	0.00602	CcSEcCtD
Fluocinonide—Dry skin—Epirubicin—ovarian cancer	0.00156	0.00598	CcSEcCtD
Fluocinonide—SMO—Signaling Pathways—DLC1—ovarian cancer	0.00155	0.00808	CbGpPWpGaD
Fluocinonide—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—MAPK1—ovarian cancer	0.00154	0.00802	CbGpPWpGaD
Fluocinonide—Pruritus—Vinorelbine—ovarian cancer	0.00154	0.0059	CcSEcCtD
Fluocinonide—Nasopharyngitis—Epirubicin—ovarian cancer	0.00152	0.00584	CcSEcCtD
Fluocinonide—Erythema—Docetaxel—ovarian cancer	0.00152	0.00583	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.00151	0.00581	CcSEcCtD
Fluocinonide—Infection—Paclitaxel—ovarian cancer	0.00145	0.00558	CcSEcCtD
Fluocinonide—Dry skin—Doxorubicin—ovarian cancer	0.00144	0.00554	CcSEcCtD
Fluocinonide—Dizziness—Vinorelbine—ovarian cancer	0.00144	0.00552	CcSEcCtD
Fluocinonide—Nervous system disorder—Paclitaxel—ovarian cancer	0.00143	0.0055	CcSEcCtD
Fluocinonide—Skin disorder—Paclitaxel—ovarian cancer	0.00142	0.00545	CcSEcCtD
Fluocinonide—Nasopharyngitis—Doxorubicin—ovarian cancer	0.00141	0.0054	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	0.00139	0.00723	CbGpPWpGaD
Fluocinonide—NR3C1—Nuclear Receptor transcription pathway—ESR1—ovarian cancer	0.00137	0.00715	CbGpPWpGaD
Fluocinonide—Rash—Vinorelbine—ovarian cancer	0.00137	0.00526	CcSEcCtD
Fluocinonide—Dermatitis—Vinorelbine—ovarian cancer	0.00137	0.00526	CcSEcCtD
Fluocinonide—Headache—Vinorelbine—ovarian cancer	0.00136	0.00523	CcSEcCtD
Fluocinonide—Methylprednisolone—ABCB1—ovarian cancer	0.00136	0.086	CrCbGaD
Fluocinonide—Hyperglycaemia—Epirubicin—ovarian cancer	0.00132	0.00509	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	0.00129	0.00669	CbGpPWpGaD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.00128	0.00493	CcSEcCtD
Fluocinonide—SMO—Signaling Pathways—BCL9—ovarian cancer	0.00126	0.00659	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	0.00126	0.00656	CbGpPWpGaD
Fluocinonide—Pain—Paclitaxel—ovarian cancer	0.00125	0.0048	CcSEcCtD
Fluocinonide—Infection—Docetaxel—ovarian cancer	0.00123	0.00473	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	0.00123	0.00638	CbGpPWpGaD
Fluocinonide—Hyperglycaemia—Doxorubicin—ovarian cancer	0.00123	0.00471	CcSEcCtD
Fluocinonide—Nervous system disorder—Docetaxel—ovarian cancer	0.00121	0.00467	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	0.00121	0.00632	CbGpPWpGaD
Fluocinonide—Skin disorder—Docetaxel—ovarian cancer	0.0012	0.00462	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	0.00118	0.00616	CbGpPWpGaD
Fluocinonide—NR3C1—Adipogenesis—GADD45A—ovarian cancer	0.00114	0.00592	CbGpPWpGaD
Fluocinonide—Hypersensitivity—Paclitaxel—ovarian cancer	0.00108	0.00414	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	0.00107	0.00557	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—ESR1—ovarian cancer	0.00107	0.00555	CbGpPWpGaD
Fluocinonide—Immune system disorder—Epirubicin—ovarian cancer	0.00106	0.00408	CcSEcCtD
Fluocinonide—Pain—Docetaxel—ovarian cancer	0.00106	0.00407	CcSEcCtD
Fluocinonide—NR3C1—Transcription factor regulation in adipogenesis—IL6—ovarian cancer	0.00105	0.00548	CbGpPWpGaD
Fluocinonide—Pruritus—Paclitaxel—ovarian cancer	0.00103	0.00397	CcSEcCtD
Fluocinonide—NR3C1—Endoderm Differentiation—APC—ovarian cancer	0.00103	0.00537	CbGpPWpGaD
Fluocinonide—Erythema—Epirubicin—ovarian cancer	0.00102	0.00393	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	0.00101	0.00526	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—DOK1—ovarian cancer	0.001	0.00521	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	0.000983	0.00512	CbGpPWpGaD
Fluocinonide—Immune system disorder—Doxorubicin—ovarian cancer	0.000983	0.00377	CcSEcCtD
Fluocinonide—Dizziness—Paclitaxel—ovarian cancer	0.000966	0.00371	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	0.000962	0.00501	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	0.000962	0.00501	CbGpPWpGaD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—ESR1—ovarian cancer	0.000949	0.00494	CbGpPWpGaD
Fluocinonide—Erythema—Doxorubicin—ovarian cancer	0.000947	0.00364	CcSEcCtD
Fluocinonide—SMO—Signaling Pathways—PPP1CC—ovarian cancer	0.00094	0.0049	CbGpPWpGaD
Fluocinonide—Betamethasone—ABCB1—ovarian cancer	0.000938	0.0594	CrCbGaD
Fluocinonide—Rash—Paclitaxel—ovarian cancer	0.000921	0.00354	CcSEcCtD
Fluocinonide—Dermatitis—Paclitaxel—ovarian cancer	0.00092	0.00354	CcSEcCtD
Fluocinonide—Headache—Paclitaxel—ovarian cancer	0.000915	0.00352	CcSEcCtD
Fluocinonide—Hypersensitivity—Docetaxel—ovarian cancer	0.000912	0.0035	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	0.000909	0.00473	CbGpPWpGaD
Fluocinonide—NR3C1—Generic Transcription Pathway—NR5A1—ovarian cancer	0.000892	0.00465	CbGpPWpGaD
Fluocinonide—Pruritus—Docetaxel—ovarian cancer	0.000876	0.00337	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000865	0.00332	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	0.000835	0.00435	CbGpPWpGaD
Fluocinonide—Infection—Epirubicin—ovarian cancer	0.00083	0.00319	CcSEcCtD
Fluocinonide—Nervous system disorder—Epirubicin—ovarian cancer	0.000819	0.00315	CcSEcCtD
Fluocinonide—Dizziness—Docetaxel—ovarian cancer	0.000819	0.00315	CcSEcCtD
Fluocinonide—Skin disorder—Epirubicin—ovarian cancer	0.000811	0.00312	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	0.000808	0.00421	CbGpPWpGaD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000801	0.00308	CcSEcCtD
Fluocinonide—Rash—Docetaxel—ovarian cancer	0.000781	0.003	CcSEcCtD
Fluocinonide—Dermatitis—Docetaxel—ovarian cancer	0.00078	0.003	CcSEcCtD
Fluocinonide—Headache—Docetaxel—ovarian cancer	0.000776	0.00298	CcSEcCtD
Fluocinonide—Infection—Doxorubicin—ovarian cancer	0.000768	0.00295	CcSEcCtD
Fluocinonide—Nervous system disorder—Doxorubicin—ovarian cancer	0.000758	0.00291	CcSEcCtD
Fluocinonide—Skin disorder—Doxorubicin—ovarian cancer	0.000751	0.00288	CcSEcCtD
Fluocinonide—NR3C1—AP-1 transcription factor network—CXCL8—ovarian cancer	0.000742	0.00386	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—CDKN1B—ovarian cancer	0.000725	0.00377	CbGpPWpGaD
Fluocinonide—Pain—Epirubicin—ovarian cancer	0.000714	0.00274	CcSEcCtD
Fluocinonide—SMO—Signaling Pathways—HDAC6—ovarian cancer	0.000712	0.00371	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—IL2—ovarian cancer	0.000709	0.00369	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—PPP2R1A—ovarian cancer	0.000703	0.00366	CbGpPWpGaD
Fluocinonide—NR3C1—Endoderm Differentiation—CTNNB1—ovarian cancer	0.000701	0.00365	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—CCND1—ovarian cancer	0.000691	0.0036	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—CTNNB1—ovarian cancer	0.000685	0.00357	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	0.000682	0.00355	CbGpPWpGaD
Fluocinonide—SMO—GPCR ligand binding—CXCL8—ovarian cancer	0.000675	0.00351	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—MMP9—ovarian cancer	0.000671	0.0035	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—PTEN—ovarian cancer	0.000667	0.00348	CbGpPWpGaD
Fluocinonide—Pain—Doxorubicin—ovarian cancer	0.000661	0.00254	CcSEcCtD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—CXCL8—ovarian cancer	0.000654	0.00341	CbGpPWpGaD
Fluocinonide—NR3C1—Adipogenesis—IL6ST—ovarian cancer	0.000639	0.00333	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—YAP1—ovarian cancer	0.000631	0.00328	CbGpPWpGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—IL2—ovarian cancer	0.000625	0.00325	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—XIAP—ovarian cancer	0.000618	0.00322	CbGpPWpGaD
Fluocinonide—Hypersensitivity—Epirubicin—ovarian cancer	0.000615	0.00236	CcSEcCtD
Fluocinonide—NR3C1—Gene Expression—WDR77—ovarian cancer	0.000603	0.00314	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—SMARCA4—ovarian cancer	0.000602	0.00313	CbGpPWpGaD
Fluocinonide—Pruritus—Epirubicin—ovarian cancer	0.000591	0.00227	CcSEcCtD
Fluocinonide—SMO—Signaling Pathways—EREG—ovarian cancer	0.000588	0.00306	CbGpPWpGaD
Fluocinonide—Hypersensitivity—Doxorubicin—ovarian cancer	0.000569	0.00219	CcSEcCtD
Fluocinonide—NR3C1—FOXA2 and FOXA3 transcription factor networks—AKT1—ovarian cancer	0.000558	0.0029	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—MYC—ovarian cancer	0.000555	0.00289	CbGpPWpGaD
Fluocinonide—Dizziness—Epirubicin—ovarian cancer	0.000552	0.00212	CcSEcCtD
Fluocinonide—SMO—Signaling Pathways—PGR—ovarian cancer	0.000551	0.00287	CbGpPWpGaD
Fluocinonide—Pruritus—Doxorubicin—ovarian cancer	0.000547	0.0021	CcSEcCtD
Fluocinonide—Dexamethasone—ABCB1—ovarian cancer	0.000546	0.0345	CrCbGaD
Fluocinonide—Rash—Epirubicin—ovarian cancer	0.000527	0.00202	CcSEcCtD
Fluocinonide—Dermatitis—Epirubicin—ovarian cancer	0.000526	0.00202	CcSEcCtD
Fluocinonide—Headache—Epirubicin—ovarian cancer	0.000523	0.00201	CcSEcCtD
Fluocinonide—SMO—Signaling Pathways—PARP1—ovarian cancer	0.000512	0.00267	CbGpPWpGaD
Fluocinonide—Dizziness—Doxorubicin—ovarian cancer	0.000511	0.00196	CcSEcCtD
Fluocinonide—NR3C1—Generic Transcription Pathway—YAP1—ovarian cancer	0.000509	0.00265	CbGpPWpGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—MAPK3—ovarian cancer	0.000502	0.00262	CbGpPWpGaD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYC—ovarian cancer	0.000494	0.00257	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—IL6ST—ovarian cancer	0.00049	0.00255	CbGpPWpGaD
Fluocinonide—Rash—Doxorubicin—ovarian cancer	0.000487	0.00187	CcSEcCtD
Fluocinonide—Dermatitis—Doxorubicin—ovarian cancer	0.000487	0.00187	CcSEcCtD
Fluocinonide—Headache—Doxorubicin—ovarian cancer	0.000484	0.00186	CcSEcCtD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—MAPK1—ovarian cancer	0.000478	0.00249	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—TTF1—ovarian cancer	0.000473	0.00246	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—PIK3CG—ovarian cancer	0.00047	0.00245	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—TP53—ovarian cancer	0.000455	0.00237	CbGpPWpGaD
Fluocinonide—NR3C1—Generic Transcription Pathway—PGR—ovarian cancer	0.000444	0.00231	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—NR5A1—ovarian cancer	0.00043	0.00224	CbGpPWpGaD
Fluocinonide—NR3C1—Adipogenesis—CTNNB1—ovarian cancer	0.000417	0.00217	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—IL6—ovarian cancer	0.000417	0.00217	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—PPP2R1A—ovarian cancer	0.000415	0.00216	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—PIK3CD—ovarian cancer	0.000414	0.00215	CbGpPWpGaD
Fluocinonide—NR3C1—Generic Transcription Pathway—PARP1—ovarian cancer	0.000413	0.00215	CbGpPWpGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—TP53—ovarian cancer	0.000401	0.00209	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—CXCL8—ovarian cancer	0.000391	0.00204	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—CASP3—ovarian cancer	0.000374	0.00195	CbGpPWpGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—IL6—ovarian cancer	0.000367	0.00191	CbGpPWpGaD
Fluocinonide—NR3C1—Adipogenesis—STAT3—ovarian cancer	0.000364	0.00189	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—CTNNB1—ovarian cancer	0.000361	0.00188	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—PIK3CB—ovarian cancer	0.00036	0.00188	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—CXCL8—ovarian cancer	0.000346	0.0018	CbGpPWpGaD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—AKT1—ovarian cancer	0.000342	0.00178	CbGpPWpGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—AKT1—ovarian cancer	0.000339	0.00176	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—IL2—ovarian cancer	0.000331	0.00172	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—TERT—ovarian cancer	0.00033	0.00172	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—VEGFA—ovarian cancer	0.000318	0.00165	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CAV1—ovarian cancer	0.000305	0.00159	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—ESR1—ovarian cancer	0.000294	0.00153	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—IL6ST—ovarian cancer	0.000289	0.00151	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—APC—ovarian cancer	0.000278	0.00145	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—PIK3CG—ovarian cancer	0.000278	0.00145	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—NRAS—ovarian cancer	0.000278	0.00145	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—MAPK3—ovarian cancer	0.000266	0.00139	CbGpPWpGaD
Fluocinonide—NR3C1—Adipogenesis—IL6—ovarian cancer	0.000254	0.00132	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—MAPK1—ovarian cancer	0.000253	0.00132	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—EGFR—ovarian cancer	0.000253	0.00132	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—YAP1—ovarian cancer	0.000245	0.00128	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—PIK3CD—ovarian cancer	0.000244	0.00127	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—KRAS—ovarian cancer	0.000239	0.00125	CbGpPWpGaD
Fluocinonide—NR3C1—Generic Transcription Pathway—ESR1—ovarian cancer	0.000237	0.00124	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—PIK3CA—ovarian cancer	0.00022	0.00114	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—IL6—ovarian cancer	0.00022	0.00114	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—ERBB2—ovarian cancer	0.000216	0.00112	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—PGR—ovarian cancer	0.000214	0.00111	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—MTOR—ovarian cancer	0.000213	0.00111	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—PIK3CB—ovarian cancer	0.000213	0.00111	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CXCL8—ovarian cancer	0.000205	0.00107	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—HRAS—ovarian cancer	0.000203	0.00106	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CDKN1B—ovarian cancer	0.0002	0.00104	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—PARP1—ovarian cancer	0.000199	0.00104	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CASP3—ovarian cancer	0.000196	0.00102	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—IL2—ovarian cancer	0.000196	0.00102	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—IL6—ovarian cancer	0.000195	0.00101	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CCND1—ovarian cancer	0.000191	0.000993	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CTNNB1—ovarian cancer	0.000189	0.000983	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—MMP9—ovarian cancer	0.000185	0.000964	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—PTEN—ovarian cancer	0.000184	0.000958	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—AKT1—ovarian cancer	0.00018	0.000935	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—VEGFA—ovarian cancer	0.000166	0.000865	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—STAT3—ovarian cancer	0.000165	0.000857	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—NRAS—ovarian cancer	0.000164	0.000855	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—PPP2R1A—ovarian cancer	0.000161	0.00084	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—MAPK3—ovarian cancer	0.000157	0.000819	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—MYC—ovarian cancer	0.000153	0.000796	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—MAPK1—ovarian cancer	0.00015	0.000779	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—EGFR—ovarian cancer	0.00015	0.000779	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—KRAS—ovarian cancer	0.000141	0.000736	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—PIK3CA—ovarian cancer	0.00013	0.000676	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—TP53—ovarian cancer	0.000126	0.000654	CbGpPWpGaD
Fluocinonide—NR3C1—Generic Transcription Pathway—MYC—ovarian cancer	0.000123	0.000643	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—HRAS—ovarian cancer	0.00012	0.000625	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—IL6—ovarian cancer	0.000115	0.000599	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—ESR1—ovarian cancer	0.000114	0.000595	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—AKT1—ovarian cancer	0.000106	0.000552	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—MAPK3—ovarian cancer	6.11e-05	0.000318	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—MYC—ovarian cancer	5.94e-05	0.000309	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—AKT1—ovarian cancer	4.12e-05	0.000215	CbGpPWpGaD
